Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-27T22:57:53.953Z Has data issue: false hasContentIssue false

369 Differentiating Dementia with Lewy Bodies and Alzheimer’s Disease Using Extracellular Vesicles

Published online by Cambridge University Press:  24 April 2023

Maria Bregendahl
Affiliation:
Mayo Clinic Graduate School of Biomedical Sciences
Ayman Faroqi
Affiliation:
(Mayo Clinic Department of Neuroscience, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA)
Zhengrong Zhang
Affiliation:
(Mayo Clinic Department of Neuroscience, Jacksonville, FL, USA)
Yang You
Affiliation:
(Mayo Clinic Department of Neuroscience, Jacksonville, FL, USA)
Tsuneya Ikezu
Affiliation:
(Mayo Clinic Department of Neuroscience, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA)
Suelen Boschen Lucio De Souza
Affiliation:
(Mayo Clinic Department of Neuroscience, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA)
Pamela McLean
Affiliation:
(Mayo Clinic Department of Neuroscience, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: Extracellular vesicles (EVs) in biofluids can reflect pathology in the brain (like alpha-synuclein protein linked to Dementia with Lewy Bodies) making them attractive disease biomarkers to distinguish disease. Here, we will investigate their potential as non-invasive biomarkers to differentiate Dementia with Lewy Bodies & Alzheimer's Disease. METHODS/STUDY POPULATION: We will leverage the collection of antemortem plasma from autopsy confirmed Dementia with Lewy Bodies (DLB), Alzheimer's Disease (AD) & healthy controls (HC) through the Mayo Clinic Brain Bank. We will characterize antemortem brain-derived plasma EVs (bPEVs) & post-mortem brain-derived EVs (bEVs) of the same patient using nanoparticle tracking, electron microscopy, & western blotting for EV-associated proteins. We will then measure levels of total & phosphorylated alpha-synuclein (asyn) using AlphaLisa. We will assess EVs' ability to initiate asyn aggregation using a real-time quaking-induced conversion (RT-QuIC) assay & a cell-based Fluorescence Resonance Energy Transfer (FRET) assay. Once characterized, this will allow differentiation of bpEVs in DLB, AD, or healthy controls. RESULTS/ANTICIPATED RESULTS: We hypothesize that asyn levels and seeding capacity will discriminate DLB from AD. With AlphaLisa assay, we expect higher total and phosphorylated asyn levels in DLB bpEVs and their corresponding post-mortem bEVs. Using RT-QuIC and FRET assay, we expect EVs isolated from DLB patient samples to support seeded aggregation, whereas EVs from AD and HC will not. DISCUSSION/SIGNIFICANCE: To date, no diagnostic or less invasive biomarkers can distinguish DLB from AD. The successful completion of the aims outlined in this proposal will identify characteristics of bpEVs that differentiate DLB from AD or HC and support the development of bpEVs as a non-invasive, early biomarker to diagnose patients presenting with dementia from DLB.

Type
Precision Medicine/Health
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2023. The Association for Clinical and Translational Science